165,166 Retatrutide has now entered Phase III clinical trials
At the same time, the pleiotropic, neurotrophic and neuroprotective properties of GLP-1RAs are also obvious and, taking into account the ability to enhance the energy metabolism of neurons and optimize synaptic plasticity these beneficial effects position GLP-1RAs as potential agents modifying brain diseases [109, 110]
The "shared mesolimbic mechanism" framing makes for a compelling narrative, but mechanistic precision matters
304 , C508518 (2013)
Hypoglycaemia associated with Mounjaro, particularly when used in combination with other glucose-lowering agents, should be coded as E16.0 (Drug-induced hypoglycaemia without coma) or E16.1 (Other hypoglycaemia) as appropriate, with additional diabetes codes (E11
This implies that, similar to other cardiovascular and metabolic treatments, people cannot discontinue the medication if they wish to maintain their weight loss